LEXICON PHARMACEUTICALS
Lexicon Pharmaceuticals, Inc. (formerly Lexicon Genetic) a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211 that has completed Phase II clinical trials to treat type 2 dia... betes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032 that has completed Phase II clinical trials to treat the symptoms associated with carcinoid syndrome. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. The company has drug discovery alliances with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It also has drug development financing collaboration with Symphony Icon; collaboration agreement with Taconic Farms, Inc.; and an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology.
LEXICON PHARMACEUTICALS
Industry:
Bioinformatics Biotechnology Medical Pharmaceutical
Founded:
1995-01-01
Address:
The Woodlands, Texas, United States
Country:
United States
Website Url:
http://www.lexpharma.com
Total Employee:
251+
Status:
Active
Contact:
281-863-3000
Email Addresses:
[email protected]
Total Funding:
448.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Universal Analytics Domain Not Resolving Apache Microsoft Exchange Online
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2001-06-13 | Coelacanth | Coelacanth acquired by Lexicon Pharmaceuticals | 32 M USD |
Investors List
Invus
Invus investment in Post-IPO Equity - Lexicon Pharmaceuticals
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Lexicon Pharmaceuticals
Invus
Invus investment in Post-IPO Equity - Lexicon Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - Lexicon Pharmaceuticals
USAMRMC
USAMRMC investment in Grant - Lexicon Pharmaceuticals
U.S. Army Medical Research & Development Command
U.S. Army Medical Research & Development Command investment in Grant - Lexicon Pharmaceuticals
Sofinov Societe Financiere D'Innovation
Sofinov Societe Financiere D'Innovation investment in Post-IPO Equity - Lexicon Pharmaceuticals
Punk, Ziegel & Company
Punk, Ziegel & Company investment in Post-IPO Equity - Lexicon Pharmaceuticals
Bay City Capital
Bay City Capital investment in Post-IPO Equity - Lexicon Pharmaceuticals
BCM Technologies (BCMT)
BCM Technologies (BCMT) investment in Post-IPO Equity - Lexicon Pharmaceuticals
Official Site Inspections
http://www.lexpharma.com Semrush global rank: 2.14 M Semrush visits lastest month: 9.37 K
- Host name: ec2-54-161-141-183.compute-1.amazonaws.com
- IP address: 54.161.141.183
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149